CENATAC-DT

Across TCGA pan-cancer cohorts, CENATAC-DT RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of CENATAC-DT’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where CENATAC-DT RNA is repressed in tumor relative to normal tissue. In most cancer types CENATAC-DT is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, KICH, and COAD are the cancer types where CENATAC-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CENATAC-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	−0.790	<.001	10	view →
KICH	Male	All	−1.019	<.001	9	view →
COAD	Male	III,IV	+0.507	.001	8	view →
BLCA	Female	III,IV	+0.674	.010	7	view →
LIHC	Male	All	+0.623	<.001	7	view →
STAD	Male	II,III,IV	+0.574	.005	2	view →
UCEC	All	All	−0.434	.037	2	view →
HNSC	All	III,IV	+0.384	.014	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

CENATAC-DT–THCA

Open the THCA breakdown →